Showing 71-80 of 1407 results for "".
Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/alpha-synuclein-a-therapeutic-target-and-potential-biomarker-in-parkinsons-disease/30407/Parkinson Disease Therapy: Lifestyle Interventions to Optimize Care
https://practicalneurology.com/diseases-diagnoses/movement-disorders/parkinson-disease-therapy-lifestyle-interventions-to-optimize-care/36278/Lisa Volenec, a patient advocate and General Manager of KMTV, Omaha, NE, shares how incorporating lifestyle modifications—such as diet, exercise, and community engagement—has enhanced her Parkinson disease treatment. She is joined by double-board-certified neurology and lifestyle medicine physician- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31184/Integrating Antidepressant Therapy in Parkinson’s Disease ManagementDepression is a common comorbidity in Parkinson’s disease (PD) patients, necessitating careful consideration for antidepressant therapy. Dr. Eric J. Ahlskog, a leading neurologist at the Mayo Clinic, emphasizes the interplay between
In the Pipeline
https://practicalneurology.com/columns/practice-management/in-the-pipeline/30821/Raising Urate With Inosine to Potentially Slow Progression of Parkinson's Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/movement-disorders-focus/30688/Results of the Phase II SURE-PD study show inosine is safe and tolerable and raises urate levels, which have been inversely related to Parkinson's progression. Still, patients are cautioned against self-medicating before the next phase of this research effort is completed.Knocking Out PD Symptoms?
https://practicalneurology.com/diseases-diagnoses/movement-disorders/knocking-out-pd-symptoms/30659/Exercise is crucial for patients with Parkinson's. One program wants to give them a fighting chance.- Can We Boost The Efficacy of Dopaminergic Therapy?https://practicalneurology.com/columns/practice-management/can-we-boost-the-efficacy-of-dopaminergic-therapy/31220/Parkinson’s disease (PD) management continues to prioritize maintaining patients' quality of life and motor function, aligning with the foundational goals established since Dr. James Parkinson’s initial descriptions in 1817. Contemporary treatment primarily focuses on dopamine replacement to counter
Update on Noninvasive Neuromodulation Devices for Headache Treatment
https://practicalneurology.com/diseases-diagnoses/headache-pain/update-on-noninvasive-neuromodulation-devices-for-headache-treatment/31283/Stewart J. Tepper, MD, Vice President of the New England Institute for Neurology and Headache, Peter McAllister, MD, FAAN, Chief Medical Officer of the New England Institute for Neurology and Headache, and Teshamae Monteith, MD, Associate Professor and Chief of the Headache Division of the DepartmenCould a Novel Oral Therapy Change How Clinicians Treat Obstructive Sleep Apnea?Insights From the SynAIRgy Trial
https://practicalneurology.com/diseases-diagnoses/sleep/could-a-novel-oral-therapy-change-how-clinicians-treat-obstructive-sleep-apnea-insights-from-the-synairgy-trial/68963/In this episode, Patrick J. Strollo Jr, MD, FACP, FCCP, FAASM, of the University of Pittsburgh Department of Medicine, Pittsburgh, PA, discusses the data from the phase 3 SynAIRgy clinical trial for AD109, an investigational once-nightly oral treatment targeting neuromuscular dysfunction in obstructDystonia and Parkinson's Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/dystonia-and-parkinsons-disease/30533/Despite its prevalence, dystonia is under-recognized and therefore undertreated.